Compare Annaly Capital Management, Inc. (NLY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Repligen Corporation Common Stock — how do they compare? Annaly Capital Management, Inc. trades at $18.32 (market cap $13.69B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Annaly Capital Management, Inc. is the larger of the two by market cap, and Annaly Capital Management, Inc. pays a 16.52% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 92 Days and Repligen Corporation Common Stock for 0 Days on average.
| NLY | RGEN | |
|---|---|---|
Market Cap | $13.69B | $11.31B |
Volume | 10,312,599 | 1,216,919 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $194.57 |
52-Week Low | $17.93 | $102.87 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $135.72B | $11.20B |
Dividend Yield | 16.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Annaly Capital Management (NLY) trades at $18.16, down 0.71% on the day, as the mortgage REIT faces technical headwinds despite strong fundamentals. The stock exhibits a bearish technical signal with key resistance at $19, while recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.79 surpassing the $0.751 consensus. NLY maintains a high dividend yield, recently declaring a $0.75 quarterly payout, supported by a 92.77% net income margin and 20.66% ROE. The company's portfolio expansion to $107 billion in 2026 drives earnings growth, though rising interest rates pose challenges.
NLY presents a value opportunity with a P/E of 4.39 and P/B of 0.91, trading below the analyst consensus price target of $22.00. The 57% buy rating from analysts reflects confidence in its dividend sustainability and portfolio strength. Key risks include sensitivity to interest rate hikes, leveraged balance sheet with debt-to-asset ratio of 23.55 in 2025, and potential volatility in mortgage spreads. Investors are compensated with a high yield, but must monitor Federal Reserve policy impacts on mortgage REIT profitability.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
